智通财经APP获悉，东阳光长江药业(01558)涨超3%，截至发稿，涨3.26%，报9.81港元，成交额2911.25万港元。
消息面上，自去年年底以来，全国多地甲流疫情呈现高发态势。据中国疾控中心最新数据显示，当前流感病毒阳性率持续上升，其中99%以上为甲型流感（甲流）。阿里健康大药房方面的数据显示，最近两周，玛巴洛沙韦、奥司他韦等相关药品搜索、需求量持续增长。1月5日，相关产品搜索需求量环比增长超过200%。
据悉，公司为流感抗病毒药物“奥司他韦”的主要生产商，可威作为公司核心产品，医院端销售占比60%左右，二级和三级医院覆盖率分别达到了70%和76%，奥司他韦产品在国内抗流感治疗领域取得领先地位。东阳光长江药业2024年半年报显示，公司以核心品种可威为代表的抗感染儿科线的销售额为18.65亿元，占总营收比重超过七成。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.